However, Bayer's top-selling pharma product Xarelto (rivaroxaban), an anticoagulant, continued to succumb to generic competition with a near-11% fall to €904 million. The solid quarter is ...

In place of managers, Bayer got rid of annual budgets and asked staff to organize themselves into 90-day “sprints” in ...

Japanese drugmaker Kyorin Pharmaceutical has entered into a licensee agreement with Bayer for the novel obstructive sleep ...

INR:6492. acerbo bayer Oral liquid consistency evaluation takes a high-end route! 3 products passed the evaluation and 16 challenged the first copy The pharmaceutica ...

Bayer AG’s revenue will not plummet even though the company is facing patent expiries for some blockbuster drugs, according to its pharma head. “The patent cliff is more of a dent than a cliff ...

German pharmaceutical giant Bayer released its third quarter 2024 earnings on Tuesday, reporting net sales of €10.0bn, down ...

In the case of the pharmaceutical segment of Bayer, the dynamics driving the results ... our continued growth momentum from our key launch products, the key question will be when exactly we ...

Bayer initiates phase I study with SOS1 inhibitor, BAY3498264 in patients with advanced KRAS-mutated tumours: Berlin Saturday, December 14, 2024, 13:00 Hrs [IST] Bayer announced i ...

Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline as well as innovations around Artificial In ...